CONDITION AND RESULTS OF OPERATIONS The following discussion analysis financial condition AbbVie Inc AbbVie company September 30 2018 December 31 2017 results operations three nine months ended September 30 2018 2017 This commentary read conjunction condensed consolidated financial statements accompanying notes appearing Item 1 Financial Statements Supplementary Data EXECUTIVE OVERVIEWCompany OverviewAbbVie global research-based biopharmaceutical company formed 2013 following separation Abbott Laboratories Abbott AbbVie uses expertise dedicated people unique approach innovation develop market advanced therapies address world complex serious diseases AbbVie products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis C HCV human immunodeficiency virus HIV neurological disorders Parkinson disease metabolic diseases including thyroid disease complications associated cystic fibrosis well serious health conditions AbbVie also pipeline promising new medicines across important medical specialties immunology oncology neuroscience additional targeted investment cystic fibrosis women health.AbbVie products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers AbbVie-owned distribution centers public warehouses In United States AbbVie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients Outside United States sales made either directly customers distributors depending market served Certain products co-marketed co-promoted companies AbbVie approximately 30,000 employees AbbVie operates one business segment pharmaceutical products.2018 Strategic ObjectivesAbbVie's mission innovation-driven patient-focused specialty biopharmaceutical company capable achieving top-tier financial performance outstanding execution consistent stream innovative new medicines AbbVie intends continue advance mission number ways including growing revenues diversifying revenue streams driving late-stage pipeline assets market ensuring strong commercial execution new product launches ii continued investment expansion pipeline support opportunities immunology oncology neurology well continued investment key on-market products iii expanding operating margins iv returning cash shareholders via dividends share repurchases In addition AbbVie anticipates several regulatory submissions key data readouts key clinical trials next twelve months.Financial ResultsThe company's financial performance nine months ended September 30 2018 included delivering worldwide net revenues 24.4 billion operating earnings 8.8 billion diluted earnings per share 4.79 cash flows operations 10.0 billion Worldwide net revenues grew 18 constant currency basis driven primarily continued strength HUMIRA revenue growth related IMBRUVICA HCV product MAVYRET.Diluted earnings per share 4.79 nine months ended September 30 2018 included following after-tax costs 801 million related amortization intangible assets ii 500 million result collaboration agreement extension Calico Life Sciences LLC Calico iii 432 million change fair value contingent consideration liabilities iv litigation reserve charges 276 million v charitable contributions 182 million part AbbVie's previously announced plan make contributions U.S not-for-profit organizations 2018 vi 124 million acquired in-process research development IPR&D vii milestone payments 87 million Financial results nine months ended September 30 2018 also impacted U.S tax reform timing new legislation's phase certain subsidiaries Additionally financial results reflected continued added funding support stages AbbVie emerging pipeline assets continued investment AbbVie growth brands.2018 Form 10-Q 26In November 2018 company announced board directors declared increase company's quarterly cash dividend 0.96 per share 1.07 per share beginning dividend payable February 2019 This reflects increase approximately 11.5 previous quarterly rate.In addition financial results AbbVie continued advance augment pipeline described heading Research Development Research DevelopmentResearch innovation cornerstones AbbVie business global biopharmaceutical company AbbVie long-term success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies.AbbVie pipeline currently includes 60 compounds indications clinical development individually collaboration license agreements focused important medical specialties immunology oncology neurology along targeted investments cystic fibrosis women health Of programs 30 mid late-stage development The following sections summarize transitions significant programs Phase 2 development Phase 3 development well developments significant Phase 3 registration programs AbbVie expects multiple Phase 2 programs transition Phase 3 programs next twelve months.Significant Programs DevelopmentsImmunologyUpadacitinib In January 2018 U.S Food Drug Administration FDA granted breakthrough therapy designation upadacitinib investigational oral JAK1-selective inhibitor adult patients moderate severe atopic dermatitis candidates systemic therapy In April 2018 AbbVie announced top-line results Phase 3 SELECT-COMPARE clinical trial evaluating upadacitinib met primary ranked secondary endpoints patients moderate severe rheumatoid arthritis RA stable background methotrexate inadequate response The safety profile upadacitinib consistent previously reported clinical trials new safety signals detected In June 2018 AbbVie announced top-line results Phase 3 SELECT-EARLY clinical trial evaluating upadacitinib versus methotrexate adult patients moderate severe RA methotrexate-na met primary ranked secondary endpoints The safety profile upadacitinib consistent previously reported clinical trials new safety signals detected In July 2018 AbbVie initiated two Phase 3 clinical trials evaluate efficacy safety upadacitinib subjects moderate severe atopic dermatitis In September 2018 AbbVie initiated Phase 3 clinical trial evaluate efficacy safety upadacitinib subjects moderate severe ulcerative colitis.Risankizumab In January 2018 AbbVie initiated two Phase 3 clinical trials evaluate efficacy safety risankizumab investigational interleukin-23 IL-23 inhibitor versus placebo induction therapy subjects moderately severely active Crohn disease In February 2018 AbbVie announced top-line results two Phase 3 clinical trials evaluating risankizumab 12-week dosing compared ustekinumab met ranked additional secondary endpoints treatment patients moderate severe chronic plaque psoriasis The initial results clinical trials previously announced October 2017 The safety profile consistent previously reported studies new safety signals detected across two studies.2018 Form 10-Q 27 In April 2018 AbbVie submitted Biologics License Application BLA FDA Marketing Authorisation Application MAA European Medicines Agency EMA risankizumab treatment plaque psoriasis adults In May 2018 AbbVie initiated Phase 2b/3 clinical trial evaluate efficacy safety risankizumab versus placebo subjects moderately severely active ulcerative colitis.OncologyIMBRUVICA In April 2018 AbbVie initiated Phase 3 clinical trial evaluate safety efficacy IMBRUVICA combination VENCLEXTA versus chlorambucil plus GAZYVA obinutuzumab first-line treatment subjects chronic lymphocytic leukemia CLL small lymphocytic lymphoma SLL In May 2018 AbbVie announced results Phase 3 iLLUMINATE study evaluating IMBRUVICA combination GAZYVA previously untreated CLL/SLL met primary endpoint In June 2018 AbbVie announced results interim analysis Phase 3 iNNOVATE study evaluating IMBRUVICA plus Rituxan rituximab previously untreated relapsed/refractory R/R patients Waldenstr macroglobulinemia WM met primary endpoint In July 2018 AbbVie announced results Phase 3 study evaluating addition IMBRUVICA chemotherapy regimen consisting five different agents used combination meet primary endpoint subset untreated diffuse large B-cell lymphoma patients identified non-germinal center B-cell activated B-cell subtypes disease In August 2018 FDA approved IMBRUVICA combination Rituxan treatment adult patients WM In October 2018 FDA accepted priority review AbbVie's supplemental New Drug Application sNDA IMBRUVICA combination GAZYVA patients previously untreated CLL/SLL.VENCLEXTA In January 2018 AbbVie submitted sNDA FDA VENCLEXTA monotherapy patients CLL refractory relapsed B-cell receptor pathway inhibitors In June 2018 FDA approved VENCLEXTA combination Rituxan treatment patients CLL/SLL without 17p deletion received least one prior therapy VENCLEXTA plus Rituxan first oral-based chemotherapy-free combination CLL allows patients option fixed treatment duration In July 2018 AbbVie submitted sNDA FDA VENCLEXTA combination hypomethylating agent combination low dose cytarabine treatment newly diagnosed patients acute myeloid leukemia ineligible intensive chemotherapy In August AbbVie granted priority review VENCLEXTA FDA In September 2018 FDA expanded label VENCLEXTA combination Rituxan include information patients previously-treated CLL achieved minimal residual disease MRD negativity Phase 3 MURANO trial In October 2018 European Commission approved type-II variation application VENCLYXTO combination Rituxan treatment patients R/R CLL received least one prior therapy In October 2018 AbbVie announced results Phase 3 CLL14 study comparing efficacy safety VENCLEXTA plus obinutuzumab versus obinutuzumab plus chlorambucil previously untreated patients CLL coexisting medical conditions met primary endpoint.2018 Form 10-Q 28Rova-T In March 2018 AbbVie announced top-line results Phase 2 TRINITY study evaluating rovalpituzumab tesirine Rova-T third-line R/R small cell lung cancer SCLC Although Rova-T demonstrated single agent responses advanced SCLC patients consulting FDA based magnitude effect across multiple parameters single-arm study company seek accelerated approval Rova-T third-line R/R SCLC Ongoing Phase 3 studies continue investigate Rova-T first second-line SCLC.Other In August 2018 Bristol-Myers Squibb Company BMS announced FDA accepted priority review supplemental Biologics License Application sBLA Empliciti elotuzumab combination pomalidomide low-dose dexamethasone treatment patients relapsed/refractory multiple myeloma RRMM received least two prior therapies This submission followed BMS announcement June 2018 results Phase 2 ELOQUENT-3 study evaluating combination Empliciti pomalidomide/dexamethasone RRMM patients met primary endpoint BMS AbbVie co-developing Empliciti BMS solely responsible commercial activities.Neurology In March 2018 Biogen AbbVie announced voluntary worldwide withdrawal marketing authorizations ZINBRYTA prescription medicine used treat adults relapsing forms multiple sclerosis.Other In February 2018 AbbVie announced top-line results Phase 3 ELARIS UF-I study evaluating elagolix investigational orally administered gonadotropin-releasing hormone GnRH antagonist investigated combination low-dose hormone add-back therapy uterine fibroids met primary efficacy endpoint ranked secondary endpoints In March 2018 AbbVie announced top-line results Phase 3 ELARIS UF-II study evaluating elagolix combination low-dose hormone add-back therapy uterine fibroids met primary efficacy endpoint ranked secondary endpoints In July 2018 FDA approved ORILISSA elagolix management moderate severe pain associated endometriosis In August 2018 AbbVie announced top-line results Phase 3 ELARIS UF-EXTEND study evaluating elagolix combination low-dose hormone therapy uterine fibroids consistent findings observed ELARIS UF-I ELARIS UF-II Phase 3 studies In October 2018 AbbVie announced assume full development commercial responsibility collaboration Galapagos discover develop new therapies treat cystic fibrosis CF Under revised agreement AbbVie assume full development commercial responsibility investigational program comprising several clinical pre-clinical compounds originally discovered developed jointly AbbVie Galapagos Galapagos pursue research development CF eligible future milestones royalties commercialized programs.For comprehensive discussion AbbVie products pipeline see company Annual Report Form 10-K year ended December 31 2017.2018 Form 10-Q 29RESULTS OF OPERATIONSNet RevenuesThe comparisons presented constant currency rates reflect comparative local currency net revenues prior year foreign exchange rates This measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods AbbVie believes non-GAAP measure change net revenues constant currency rates used conjunction GAAP measure change net revenues actual currency rates may provide complete understanding company operations facilitate analysis company results operations particularly evaluating performance one period another Three months endedSeptember 30 Percent change Nine months endedSeptember 30 Percent change At actual currency rates At constant currency rates At actual currency rates At constant currency rates(dollars millions 2018 2017 20182017 United States $5,597 $4,586 22.0 22.0 15,836 $13,284 19.2 19.2%International 2,639 2,409 9.6 11.7 8,612 7,193 19.7 15.3%Net revenues $8,236 $6,995 17.8 18.5 24,448 $20,477 19.4 17.8%2018 Form 10-Q 30The following table details AbbVie worldwide net revenues Three months endedSeptember 30 Percent change Nine months endedSeptember 30 Percent change At actual currency rates At constant currency rates At actual currency rates At constant currency rates(dollars millions 2018 2017 2018 2017 Immunology HUMIRA United States $3,546 $3,151 12.5 12.5 10,070 $9,048 11.3 11.3 %International 1,578 1,550 1.8 4.2 4,948 4,487 10.3 5.9 %Total $5,124 $4,701 9.0 9.8 15,018 $13,535 11.0 9.5 %Hematologic Oncology IMBRUVICA United States $812 $574 41.5 41.5 2,129 $1,559 36.6 36.6 %Collaboration revenues 160 114 40.1 40.1 455 306 48.5 48.5 %Total $972 $688 41.3 41.3 2,584 $1,865 38.5 38.5 %VENCLEXTA United States $69 $25 >100.0 100.0 157 $60 >100.0 100.0%International 27 8 >100.0 100.0 63 18 >100.0 100.0%Total $96 $33 >100.0 100.0 220 $78 >100.0 100.0%HCV MAVYRET United States $444 $60 >100.0 100.0 1,206 $60 >100.0 100.0%International 395 35 >100.0 100.0 1,413 35 >100.0 100.0%Total $839 $95 >100.0 100.0 2,619 $95 >100.0 100.0%VIEKIRA United States n/m n/m $3 $64 (96.3 96.3 International 23 181 (87.0 86.1 132 605 (78.1 78.9 Total $23 $181 (87.1 86.2 135 $669 (79.8 80.6 Other Key Products Creon United States $239 $215 11.3 11.3 667 $596 11.8 11.8 %Lupron United States $173 $161 7.6 7.6 530 $488 8.7 8.7 %International 41 40 1.5 7.2 126 117 7.4 6.9 %Total $214 $201 6.4 7.5 656 $605 8.4 8.3 %Synthroid United States $192 $191 0.7 0.7 567 $576 (1.5 1.5 Synagis International $97 $116 (16.2 14.1 462 $456 1.3 2.2 AndroGel United States $135 $147 (8.3 8.3 393 $437 (10.1 10.1 Duodopa United States $19 $16 18.7 18.7 57 $44 30.0 30.0 %International 87 78 10.8 12.2 260 211 22.8 15.6 %Total $106 $94 12.1 13.3 317 $255 24.0 18.1 %Sevoflurane United States $18 $19 (2.8 2.8 54 $56 (2.8 2.8 International 68 81 (15.7 12.2 251 255 (1.5 2.8 Total $86 $100 (13.2 10.4 305 $311 (1.7 2.7 Kaletra United States $16 $16 (2.9 2.9 42 $54 (21.4 21.4 International 72 69 5.3 8.2 210 256 (18.1 19.0 Total $88 $85 3.7 6.0 252 $310 (18.7 19.5 All $25 $148 (82.7 82.0 253 $689 (63.1 73.8 Total net revenues $8,236 $6,995 17.8 18.5 24,448 $20,477 19.4 17.8 %n/m Not meaningful2018 Form 10-Q 31The following discussion analysis AbbVie net revenues product presented constant currency basis.Global HUMIRA sales increased 10 three months 9 nine months ended September 30 2018 primarily result market growth across therapeutic categories geographies well favorable pricing certain geographies In United States HUMIRA sales increased 13 three months 11 nine months ended September 30 2018 driven market growth across indications favorable pricing Internationally HUMIRA sales increased 4 three months 6 nine months ended September 30 2018 driven primarily market growth across indications In October 2018 European Union composition matter patent adalimumab expired biosimilars HUMIRA launched Europe Biosimilar competition expected United States 2023 AbbVie continues pursue strategies intended differentiate HUMIRA competing products add sustainability future growth HUMIRA.Net revenues IMBRUVICA represent product sales United States collaboration revenues outside United States related AbbVie 50 share IMBRUVICA profit AbbVie's global IMBRUVICA revenues increased 41 three months 39 nine months ended September 30 2018 result continued penetration IMBRUVICA patients chronic lymphocytic leukemia CLL well favorable pricing.Global HCV sales increased 100 three nine months ended September 30 2018 result launch MAVYRET certain geographies beginning second half 2017 partially offset decrease revenues VIEKIRA.Net revenues Creon increased 11 three months 12 nine months ended September 30 2018 driven primarily continued market growth higher market share Creon maintains market leadership pancreatic enzyme market.Net revenues Duodopa increased 13 three months 18 nine months ended September 30 2018 primarily result increased market penetration Gross Margin Three months endedSeptember 30 Nine months endedSeptember 30 dollars millions 2018 2017 change 2018 2017 changeGross margin $6,401 $5,379 19 18,752 $15,716 19%as net revenues 78 77 77 77 Gross margin percentage net revenues increased three months flat nine months ended September 30 2018 compared prior year Gross margin percentage three months ended September 30 2018 favorably impacted reduction HUMIRA royalty expense foreign exchange partially offset IMBRUVICA profit sharing arrangement Gross margin percentage nine months ended September 30 2018 favorably impacted reduction HUMIRA royalty expense offset IMBRUVICA profit sharing arrangement foreign exchange.Selling General Administrative Three months endedSeptember 30,Nine months endedSeptember 30 dollars millions 2018 2017 change20182017 changeSelling general administrative 1,919 $1,457 32 5,470 $4,339 26%as net revenues 23 21 22 21 Selling general administrative SG&A expenses percentage net revenues increased three nine months ended September 30 2018 compared prior year SG&A expense percentage unfavorably impacted litigation reserves charges increased 224 million three months 249 million nine months ended September 30 2018 compared prior year charitable contributions 115 million three months 235 million nine months ended September 30 2018 select organizations part AbbVie's previously announced plan make 350 million contributions U.S not-for-profit organizations 2018 Additionally new product launch expenses unfavorably impacted SG&A expense percentage three nine months ended September 30 2018.2018 Form 10-Q 32Research Development Acquired In-Process Research Development Three months endedSeptember 30 Nine months endedSeptember 30 dollars millions 2018 2017 change 2018 2017 changeResearch development $1,268 $1,228 3 3,834 $3,599 7%as net revenues 15 18 16 18 Acquired in-process research development $55 n/m $124 $15 >100%Research Development R&D expenses three nine months ended September 30 2018 increased compared prior year principally due increased funding support stages company pipeline assets.Acquired in-process research development IPR&D expenses reflect upfront payments related various collaborations There individually significant transactions three nine months ended September 30 2018 2017.Other Operating ExpensesOther operating expenses nine months ended September 30 2018 included 500 million charge related extension previously announced Calico collaboration discover develop bring market new therapies patients age-related diseases including neurodegeneration cancer.Other Non-Operating Expenses Three months endedSeptember 30 Nine months endedSeptember 30 millions 2018 2017 2018 2017Interest expense $339 $293 $968 $851Interest income (37 41 143 99)Interest expense net $302 $252 $825 $752 Net foreign exchange loss $2 $9 $18 $28Other expense net 94 338 411 449Interest expense net increased three nine months ended September 30 2018 compared prior year primarily due unfavorable impact higher interest rates company's debt obligations.Other expense net included charges related changes fair value Boehringer Ingelheim Stemcentrx contingent consideration liabilities 95 million three months 432 million nine months ended September 30 2018 compared charges 401 million three months 547 million nine months ended September 30 2017 The fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatory/commercial milestones discount rates market-based factors For three months ended September 30 2018 change fair value primarily represented passage time For nine months ended September 30 2018 change fair value represented higher estimated future sales passage time partially offset effect rising interest rates For three nine months ended September 30 2017 change fair value represented mainly higher probabilities success passage time.Income Tax ExpenseThe effective tax rate 1 three nine months ended September 30 2018 22 three months 20 nine months ended September 30 2017 The effective tax rate period differed U.S statutory tax rates 21 2018 35 2017 principally due benefit foreign operations reflects impact lower income tax rates locations outside United States tax exemptions incentives Puerto Rico foreign tax jurisdictions business development activities.2018 Form 10-Q 33The change effective tax rate three nine months ended September 30 2018 prior year principally due effects enactment Tax Cuts Jobs Act Act December 2017 The Act significantly changes U.S corporate tax system reducing U.S federal corporate tax rate 35 21 requiring companies pay one-time transition tax mandatory deemed repatriation earnings certain foreign subsidiaries previously untaxed creating new taxes certain foreign sourced earnings The Act also creates territorial tax system generally excludes dividends foreign subsidiaries U.S taxation Specific 2018 beneficial impact due timing provisions related earnings certain foreign subsidiaries.FINANCIAL POSITION LIQUIDITY AND CAPITAL RESOURCES Nine months endedSeptember 30 millions)2018 2017Cash flows provided used Operating activities$10,035 $7,376Investing activities(723 475)Financing activities(10,571 3,584)Operating cash flows nine months ended September 30 2018 increased prior year due improved results operations resulting revenue growth improvement operating earnings Operating cash flows also reflected AbbVie voluntary contributions principal domestic defined benefit plan 150 million nine months ended September 30 2018 2017 The company also made additional voluntary contribution 600 million various defined benefit plans 2018.Investing cash flows nine months ended September 30 2018 included payments made acquisitions investments 541 million capital expenditures 515 million net sales maturities investment securities totaling 333 million Investing cash flows nine months ended September 30 2017 included capital expenditures 347 million payments made acquisitions investments 180 million net sales maturities investment securities totaling 52 million.Financing cash flows nine months ended September 30 2018 included proceeds issuance 3.0 billion 364-day term loan credit agreement term loan entered May 2018 In June 2018 company drew term loan September 30 2018 3.0 billion outstanding included short-term borrowings condensed consolidated balance sheet Borrowings term loan bear interest one month LIBOR plus applicable margin The term loan may prepaid without penalty upon prior notice contains customary covenants company compliance September 30 2018 In September 2018 company issued 6.0 billion aggregate principal amount unsecured senior notes The company used portion proceeds repay company's outstanding 2.0 billion term loan due mature November 2018 Financing cash flows nine months ended September 30 2018 also included May 2018 repayment 3.0 billion aggregate principal amount company's 1.80 senior notes maturity.The company made cash dividend payments 4.1 billion nine months ended September 30 2018 3.1 billion nine months ended September 30 2017 The increase cash dividend payments driven increase quarterly dividend rate On September 7 2018 board directors declared quarterly cash dividend 0.96 per share stockholders record close business October 15 2018 payable November 15 2018 On November 2 2018 company announced board directors declared increase company's quarterly cash dividend 0.96 per share 1.07 per share beginning dividend payable February 15 2019 stockholders record January 15 2019 This reflects increase approximately 11.5 previous quarterly rate The timing declaration amount payment dividends AbbVie future within discretion board directors depend upon many factors including AbbVie financial condition earnings capital requirements operating subsidiaries covenants associated certain AbbVie debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors.On February 15 2018 AbbVie's board directors authorized new 10.0 billion stock repurchase program superseded AbbVie's previous stock repurchase program The new stock repurchase program permits purchases AbbVie shares time time open-market private transactions including accelerated share repurchases management's discretion The program 2018 Form 10-Q 34no time limit discontinued time Under new authorization AbbVie repurchased 83.2 million shares 8.5 billion nine months ended September 30 2018.Prior new 10.0 billion authorization AbbVie repurchased 10.9 million shares open market 1.3 billion nine months ended September 30 2018.During nine months ended September 30 2018 AbbVie paid 100 million contingent consideration Boehringer Ingelheim related BLA MAA acceptance milestones 78 million payments included financing cash flows 22 million payments included operating cash flows During nine months ended September 30 2017 AbbVie paid 305 million contingent consideration BI related Phase 3 enrollment milestone 268 million milestone included financing cash flows 37 million included operating cash flows.During nine months ended September 30 2018 2017 company issued redeemed commercial paper The balance commercial paper outstanding 400 million December 31 2017 There commercial paper borrowings outstanding September 30 2018 AbbVie may issue additional commercial paper retire commercial paper meet liquidity requirements needed Credit RiskAbbVie monitors economic conditions creditworthiness customers government regulations funding domestically abroad AbbVie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables AbbVie establishes allowance accounts receivable probable collected AbbVie may also utilize factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables.AbbVie continues business foreign governments certain countries including Greece Portugal Italy Spain historically experienced challenges credit economic conditions Substantially AbbVie trade receivables Greece Portugal Italy Spain government health systems Outstanding governmental receivables countries net allowances doubtful accounts totaled 270 million September 30 2018 255 million December 31 2017 The company also continues business foreign governments certain oil-exporting countries experienced deterioration economic conditions including Saudi Arabia Russia may result delays collection receivables Outstanding governmental receivables related Saudi Arabia net allowances doubtful accounts 147 million September 30 2018 149 million December 31 2017 Outstanding governmental receivables related Russia net allowances doubtful accounts 104 million September 30 2018 152 million December 31 2017 Global economic conditions customer-specific factors may require company periodically re-evaluate collectability receivables company could potentially incur credit losses.Currently AbbVie believe economic conditions oil-exporting countries significant impact company liquidity cash flow financial flexibility However government funding become unavailable countries significant adverse changes reimbursement practices occur AbbVie may able collect entire balance outstanding September 30 2018.Credit Facility Access Capital Credit RatingsCredit FacilityIn September 2018 AbbVie replaced existing revolving credit facility new 3.0 billion five-year revolving credit facility The new facility enables company borrow funds unsecured basis variable interest rates contains various covenants At September 30 2018 company compliance credit facility covenants Commitment fees credit facility insignificant There amounts outstanding company's credit facilities September 30 2018 December 31 2017.Access CapitalThe company intends fund short-term long-term financial obligations mature cash hand future cash flows operations issuing additional debt The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand 2018 Form 10-Q 35company products solvency customers suppliers deterioration company key financial ratios credit ratings material unfavorable changes business conditions At current time company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives.Credit RatingsThere changes company credit ratings nine months ended September 30 2018 Unfavorable changes ratings may adverse impact future financing arrangements however would affect company ability draw credit facility would result acceleration scheduled maturities company outstanding debt CRITICAL ACCOUNTING POLICIESA summary company significant accounting policies included Note 2 Summary Significant Accounting Policies AbbVie's Annual Report Form 10-K year ended December 31 2017 Significant changes company application critical accounting policies include adoption new accounting standard establishes new revenue recognition framework See Notes 1 2 condensed consolidated financial statements additional information FORWARD-LOOKING STATEMENTSSome statements quarterly report Form 10-Q may forward-looking statements purposes Private Securities Litigation Reform Act 1995 The words believe expect anticipate project similar expressions among others generally identify forward-looking statements AbbVie cautions forward-looking statements subject risks uncertainties may cause actual results differ materially indicated forward-looking statements Such risks uncertainties include limited challenges intellectual property competition products difficulties inherent research development process adverse litigation government action changes laws regulations applicable industry Additional information economic competitive governmental technological factors may affect AbbVie operations set forth Item 1A Risk Factors AbbVie Annual Report Form 10-K year ended December 31 2017 filed Securities Exchange Commission AbbVie notes factors investors permitted Private Securities Litigation Reform Act 1995 AbbVie undertakes obligation release publicly revisions forward-looking statements result subsequent events developments except required law.ITEM 3 QUANTITATIVE AND QUALITATIVE